Pasar al contenido principal

TERAPIAS PERSONALIZADAS EN CANCER DE PANCREAS

PRE2022-102952

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance

  • Liaki, Vasiliki
  • Barrambana, Sara
  • Kostopoulou, Myrto
  • Lechuga, Carmen G
  • Zamorano-Dominguez, Elena
  • Acosta, Domingo
  • Morales-Cacho, Lucia
  • Álvarez, Ruth
  • Sun, Pian
  • Rosas-Perez, Blanca
  • Barrero, Rebeca
  • Jiménez-Parrado, Silvia
  • López-García, Alejandra
  • San Roman, Marta
  • López-Gil, Juan Carlos
  • Drosten, Matthias
  • Sainz, Bruno Jr.
  • Musteanu, Mónica
  • Caleiras, Eduardo
  • Dusetti, Nelson
  • Poli, Valeria
  • Sánchez-Bueno, Francisco
  • Guerra, Carmen
  • Barbacid, Mariano
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest cancer survival rates. Recent studies using RAS inhibitors have opened the door to more efficacious therapies, although their beneficial effect is still limited mainly due to the rapid appearance of tumor resistance. Here, we demonstrate that genetic ablation of three independent nodes involved in downstream (RAF1), upstream (EGFR), and orthogonal (STAT3) KRAS signaling pathways leads to complete and permanent regression of orthotopic PDACs induced by KRAS/TP53 mutations. Likewise, a combination of selective inhibitors of KRAS (RMC-6236/daraxonrasib), EGFR family (afatinib), and STAT3 (SD36) induced the complete regression of orthotopic PDAC tumors with no evidence of tumor resistance for over 200 d posttreatment. This combination therapy also led to significant regression of genetically engineered mouse tumors as well as patient-derived tumor xenografts (PDX) in the absence of tumor relapses. Of importance, this combination therapy was well tolerated. In sum, these results should guide the development of new clinical trials that may benefit PDAC patients., This work was supported by grants from the CRIS Cancer Foundation, the European Research Council (ERC-AG/695566-THERACAN), the Agencia Estatal de Investigación cofunded with the European Regional Development Fund (ERDF-EU ERDF) (PID2021-124106OB-I00; MCIU/AEI/10.13039/501100011033), and the European Union “NextGenerationEU”/PRTR” (PLEC2022-009255;MCIU/AEI/10.13039/501100011033) to M.B. C.G. and M.B. are recipients of a CIBERONC Fund (CB21/12/00121). Additional funding included grants from the Instituto de Salud Carlos III cofunded by ERDF (PI19/00514), the “Carmen Delgado/Miguel Pérez Mateo Grants of the “Asociación Cancer de Páncreas” to C.G., the Italian Cancer Research Association (AIRC, IG16930), and the Italian Ministry of University and Research (MIUR PRIN 2017) to V.P. M.B. is the recipient of an Endowed Chair from the AXA Research Fund. V.L. was supported by an INPhINIT fellowship from “La Caixa” Foundation (LCF/BQ/DI18/11660011) and a contract from the CRIS Cancer Foundation. S.B. is supported by a PhD scholarship from the Foundation of Science and Technology of Portugal (10.54499/2021.05875.BD). M.K. was supported by an Erasmus+ scholarship for traineeship. L.M.-C. was supported by an FPU fellowship from the Ministerio de Educación. J.C.L-G. is supported by a postdoctoral fellowship from Amigos del CNIO, E.Z.-D. is supported by a FPI fellowship (PRE2022-102952) from the Spanish Ministry of Sciences and Innovation (PID2021-124106OB-I00). P.S. is partially supported by a fellowship from the China Scholarship Council., Peer reviewed